Cai et al. reported that RYR2 is a frequently mutated gene with predicted neoantigens presented by MHC class I and class II molecules and thus is a candidate for lung adenocarcinoma immunotherapy [39]. The gene discussed is HLA-C; the disease is lung adenocarcinoma.